Further data from ongoing RCTs are needed to correctly assess the benefits of using IL-6 inhibitors to manage COVID-19, including the timing and route of administration and different patient populations, which will provide a more detailed understanding of whether this therapy is effective. Here, IL6 is linked to COVID-19.